Skip to main content
Erschienen in: Wiener klinische Wochenschrift 7-8/2014

01.04.2014 | original article

Human immunodeficiency virus type 2 infections in Austria

verfasst von: Ninon Taylor, MD, Jan Marco Kern, Wolfgang Prammer, Alois Lang, Bernhard Haas, Martin Gisinger, Robert Zangerle, Alexander Egle, Richard Greil, Hannes Oberkofler, Josef Eberle

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2014

Einloggen, um Zugang zu erhalten

Summary

Introduction

The first case of human immunodeficiency virus type 2 (HIV-2) seropositivity in Austria was confirmed in 1993 in a dually human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected patient from Ghana, who died in 2001. Before this investigation, no further HIV-2 infection was published.

Methods

The aim of this study was to describe HIV-2 epidemiology in Austria, using serological and molecular techniques, and to perform a sequence analysis of the circulating viral strains.

Results

Six additional cases of HIV-2 were identified from 2000 to 2009. All patients originated from high-prevalence areas. In one patient, the HIV-2 infection was revealed 11 years after initial HIV-1 diagnosis, and further analysis confirmed a dual infection.

Conclusion

The HIV-2 epidemic has its epicentre in West Africa, but sociocultural issues, especially migration, are contributing to the low but continuous worldwide spread of HIV-2. Diagnosis of HIV-2 implies a different therapeutical management to avoid treatment failure and clinical progression. Differential diagnosis of HIV-1 and HIV-2 is complicated due to antibody cross-reactivity, and paradoxical findings (e.g. declining CD4 cell count despite HIV-1 suppression) may require careful reassessment, especially in patients from endemic countries.
Literatur
1.
Zurück zum Zitat Clavel F, Guétard D, Brun-Vézinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233:343–6.PubMedCrossRef Clavel F, Guétard D, Brun-Vézinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233:343–6.PubMedCrossRef
2.
Zurück zum Zitat Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new diagnoses in France: 2003–2006. AIDS. 2007;21:2351–3.PubMedCrossRef Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new diagnoses in France: 2003–2006. AIDS. 2007;21:2351–3.PubMedCrossRef
3.
Zurück zum Zitat Soriano V, Gomes P, Heneine W, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol. 2000;61:111–6.PubMedCrossRef Soriano V, Gomes P, Heneine W, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol. 2000;61:111–6.PubMedCrossRef
4.
Zurück zum Zitat Dougan S, Patel B, Tosswill JH, Sinka K. Diagnoses of HIV-1 and HIV-2 in England, Wales, and Northern Ireland associated with west Africa. Sex Transm Infect. 2005;81:338–41.PubMedCentralPubMedCrossRef Dougan S, Patel B, Tosswill JH, Sinka K. Diagnoses of HIV-1 and HIV-2 in England, Wales, and Northern Ireland associated with west Africa. Sex Transm Infect. 2005;81:338–41.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Damond F, Worobey M, Campa P, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses. 2004;6:666–72.CrossRef Damond F, Worobey M, Campa P, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses. 2004;6:666–72.CrossRef
6.
Zurück zum Zitat Alabi AS, Jaffar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS. 2003;17:1513–20.PubMedCrossRef Alabi AS, Jaffar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS. 2003;17:1513–20.PubMedCrossRef
7.
Zurück zum Zitat Berry N, Ariyoshi K, Jaffar S, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1998;1:457–68.PubMed Berry N, Ariyoshi K, Jaffar S, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1998;1:457–68.PubMed
8.
Zurück zum Zitat Kanki PJ, Travers KU, M’Boup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet. 1994;343:943–6.PubMedCrossRef Kanki PJ, Travers KU, M’Boup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet. 1994;343:943–6.PubMedCrossRef
9.
Zurück zum Zitat De Silva TI, Peng Y, Ledigdowicz A, et al. Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood. 2013;121(21):4330–9.PubMedCrossRef De Silva TI, Peng Y, Ledigdowicz A, et al. Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood. 2013;121(21):4330–9.PubMedCrossRef
10.
Zurück zum Zitat Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet. 1997;349:911–4.PubMedCrossRef Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet. 1997;349:911–4.PubMedCrossRef
11.
Zurück zum Zitat Leligdowicz A, Rowland-Jones S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines. 2008;7:319–31.PubMedCrossRef Leligdowicz A, Rowland-Jones S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines. 2008;7:319–31.PubMedCrossRef
12.
Zurück zum Zitat Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57–65.PubMed Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57–65.PubMed
13.
Zurück zum Zitat Möst J, Spötl L, Sarcletti M, Vogetseder W, Dierich MP, Zangerle R. Differences in heterosexual transmission of HIV-1 and HIV-2. Lancet. 1994;344:1572–3.PubMedCrossRef Möst J, Spötl L, Sarcletti M, Vogetseder W, Dierich MP, Zangerle R. Differences in heterosexual transmission of HIV-1 and HIV-2. Lancet. 1994;344:1572–3.PubMedCrossRef
14.
Zurück zum Zitat Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.PubMedCrossRef Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.PubMedCrossRef
15.
Zurück zum Zitat Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–25.PubMed Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–25.PubMed
16.
Zurück zum Zitat Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution Int J org Evolution. 1985;39:783–91.CrossRef Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution Int J org Evolution. 1985;39:783–91.CrossRef
17.
Zurück zum Zitat Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A. 2004;101:11030–5.PubMedCentralPubMedCrossRef Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci U S A. 2004;101:11030–5.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microb. 2008;46:2088–91.CrossRef Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microb. 2008;46:2088–91.CrossRef
19.
Zurück zum Zitat Torian L, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000–2008. Clin Infect Dis. 2010;51:1334–42.PubMedCrossRef Torian L, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000–2008. Clin Infect Dis. 2010;51:1334–42.PubMedCrossRef
20.
Zurück zum Zitat Günthard HF, Huber M, Kuster H, et al. HIV-1 superinfection in an HIV-2 infected woman with subsequent control of HIV-1 plasma viremia. Clin Infect Dis. 2009;48:117–20.CrossRef Günthard HF, Huber M, Kuster H, et al. HIV-1 superinfection in an HIV-2 infected woman with subsequent control of HIV-1 plasma viremia. Clin Infect Dis. 2009;48:117–20.CrossRef
Metadaten
Titel
Human immunodeficiency virus type 2 infections in Austria
verfasst von
Ninon Taylor, MD
Jan Marco Kern
Wolfgang Prammer
Alois Lang
Bernhard Haas
Martin Gisinger
Robert Zangerle
Alexander Egle
Richard Greil
Hannes Oberkofler
Josef Eberle
Publikationsdatum
01.04.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0493-1

Weitere Artikel der Ausgabe 7-8/2014

Wiener klinische Wochenschrift 7-8/2014 Zur Ausgabe

gesellschaft der ärzte in wien

gesellschaft der ärzte in wien